microRNA signatures in prodromal REM sleep behavior disorder and early Parkinson's disease as noninvasive biomarkers

Sleep Med. 2021 Feb:78:160-168. doi: 10.1016/j.sleep.2020.12.012. Epub 2021 Jan 6.

Abstract

The flow of gene expression or "The central dogma of molecular biology": DNA - RNA - protein, proposed by Watson & Crick sixty years ago, is a tightly controlled cell process. In the middle of this journey, the mRNA molecule is regulated by "RNA interference" (RNAi), a posttranscriptional gene silencing mechanism. A microRNA is an endogenous short double-stranded RNA that down-regulates hundreds of mRNAs by RNAi, maintaining healthy cell physiology. In contrast, aberrant expressions of microRNAs play a role in Parkinson's disease (PD) pathogenesis. The damage may start at an early period of brain degeneration, in the non-motor or "prodromal" stage, where autonomic, mood and sleep changes are often manifested. REM-sleep behavior disorder (RBD) is the prodromal manifestation with the highest odds for conversion into PD, thereby a valuable phenotype for disease prediction. The present review focuses on microRNAs' role in the pathogenesis of PD and RBD, summarizing the state-of-the-art of these RNA molecules as noninvasive biomarkers for non-motor prodromal (RBD) and early PD.

Keywords: Biomarker; Parkinson's disease; RBD; REM sleep; Synucleinopathy; microRNA.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers
  • Humans
  • MicroRNAs* / genetics
  • Parkinson Disease* / genetics
  • Prodromal Symptoms
  • REM Sleep Behavior Disorder* / diagnosis
  • REM Sleep Behavior Disorder* / genetics

Substances

  • Biomarkers
  • MicroRNAs